Pathophysiology and Management of Acute Respiratory Distress Syndrome

Acute respiratory distress syndrome (ARDS) is an acute inflammatory lung condition characterised by diffuse alveolar damage, increased capillary permeability and severe hypoxaemia refractory to oxygen therapy. It may follow direct pulmonary insults such as pneumonia, aspiration or inhalational injury, or indirect insults including sepsis, pancreatitis and major trauma. Initial disruption of the alveolar epithelial–endothelial barrier permits protein-rich oedema to accumulate in airspaces, triggering neutrophil influx, cytokine release and surfactant dysfunction. A proliferative repair phase ensues, but persistent injury can lead to fibroproliferation, reduced compliance and long-term impairment. Management centres on lung-protective ventilation with low tidal volumes, limited plateau pressures and optimised positive end-expiratory pressure to recruit collapsed units without overdistension. Prone positioning and conservative fluid strategies further improve oxygenation and outcome. Adjunctive measures under active investigation include modulation of dysregulated inflammation, cell-based therapies to restore barrier integrity and personalised approaches driven by biomarker-defined subphenotypes. Early recognition of endothelial injury, epithelial dysfunction and distinct biological endotypes promises to refine risk stratification and guide targeted interventions, yet specific pharmacotherapies remain elusive and represent a major research priority worldwide.

Research from Nature Portfolio

Recent work has demonstrated the therapeutic potential of targeting the receptor for advanced glycation end-products (RAGE) axis to mitigate alveolar injury in experimental models. Inhibition of RAGE signalling by monoclonal antibodies or by administration of soluble decoy receptors attenuates inflammation, preserves epithelial channel expression and enhances alveolar fluid clearance in murine lung injury. Complementary clinical studies have identified elevated plasma RAGE isoforms as early predictors of ARDS development in at-risk intensive care cohorts, suggesting that RAGE measurement could aid in prognostic enrichment and early intervention strategies.

Pathophysiology and Management of Acute Respiratory Distress Syndrome publication trend

The graph below shows the total number of articles in pathophysiology and management of acute respiratory distress syndrome across all publications each year (not limited to Nature Index journals).

Technical terms

Alveolar fluid clearance (AFC): Active removal of fluid from the alveolar space via epithelial sodium transport to maintain efficient gas exchange.

Receptor for advanced glycation end-products (RAGE): A multiligand cell-surface receptor on alveolar epithelium that amplifies inflammatory responses upon ligand binding.

Hypoinflammatory phenotype: An ARDS subgroup defined by lower systemic cytokine concentrations, preserved lung compliance and a more rapid clinical recovery.

Endothelial barrier dysfunction: Loss of integrity in pulmonary capillary endothelium, leading to increased vascular permeability and protein-rich oedema.

MicroRNA-1 (miR-1): A small non-coding RNA that regulates gene expression to protect endothelial cells by inhibiting cell death pathways and stabilising junctional proteins.

References

1. Rapidly improving ARDS differs clinically and biologically from persistent ARDS. Critical Care (2024).
2. Endothelial cell dynamics in sepsis-induced acute lung injury and acute respiratory distress syndrome: pathogenesis and therapeutic implications. Cell Communication and Signaling (2024).
3. MicroRNA-1 protects the endothelium in acute lung injury. JCI Insight (2023).
4. RAGE inhibition reduces acute lung injury in mice. Scientific Reports (2017).
5. Receptor for advanced glycation end-products and ARDS prediction: a multicentre observational study. Scientific Reports (2018).